Find Articles



Return to:Chemistry Articles
Or:Recent Chemistry Articles

AVI BioPharma Provides Update on Clinical Trial for Treatment of ...


http://www.forbes.com/businesswire/feeds/businesswire/200...

Forbes - AVI's proprietary third-generation NEUGENE(R) chemistry can be used to target splice-joining sites in the pre-RNA, thus forcing the cell machinery to skip over targeted exons, providing altered mRNA, which in turn produces altered proteins. When the ...



Article Finder:

October 26, 2007 05:59:00 AM
Article Directory